

**Clinical Trials Summary for out of hours  
Important Reference**



**Lancashire Teaching  
Hospitals**

NHS Foundation Trust

<b>Acronym study title</b>	AURORA Study IRAS No 1004493
<b>Study Details</b>	Atezolizumab in patients with urinary tract squamous cell carcinoma: a single arm, open label, multicentre, phase II clinical trial -AURORA Study
<b>Principal Investigator PI Sub PI's</b>	<b>PI</b> – Prof Alison Birtle <b>Sub Investigator</b> – Omi Parikh & Natalie Charnley
<b>Research Nurse Team</b>	<b>Research Nurse</b> - Sirjana Devkota <b>CTSO</b> – Nathan Fish
<b>Drug therapy</b>	<b>Atezolizumab fixed standard dose 1680mg given every 28 days for up to 1 year (13 doses) or until progressive disease, unacceptable toxicity or patient/Investigators choice.</b>
<b>In the event that a patient calls this hotline for advise</b>	Refer to protocol for toxicity management.